CHROMOGRANIN A AS MARKER OF BLADDER CANCER Russian patent published in 2022 - IPC G01N33/574 

FIELD: medicine.

SUBSTANCE: invention relates to prediction of bladder cancer. A method for prediction of non-neuroendocrine bladder cancer in an individual includes determination of a level of CgA in a sample of individual’s body fluid. If the level of CgA is higher than a predetermined threshold, then it is an indicator of a high risk of death related to malignant tumor after surgical treatment, and/or treatment using a drug, and/or radiotherapy. In a patient subjected to transurethral resection of the bladder, a twenty-month survival rate after treatment is 87% for patients with low preoperational CgA concentration and 70% for patients with a high preoperational level of CgA. In a patient subjected to radical cystectomy, a twenty-month survival rate after treatment is 76% for patients with low preoperational CgA concentration and from 33% for patients with a high preoperational level of CgA. The level of CgA is considered compared to a control level or the predetermined threshold, where the latter is from 100 ng/mg to 147 ng/ml, and serum samples of healthy individuals without malignant tumor in the history are used as control.

EFFECT: invention provides prediction of bladder cancer.

6 cl, 3 dwg, 10 tbl, 3 ex